US20200147280A1 - Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds - Google Patents

Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds Download PDF

Info

Publication number
US20200147280A1
US20200147280A1 US16/733,055 US202016733055A US2020147280A1 US 20200147280 A1 US20200147280 A1 US 20200147280A1 US 202016733055 A US202016733055 A US 202016733055A US 2020147280 A1 US2020147280 A1 US 2020147280A1
Authority
US
United States
Prior art keywords
microstrain
manifold
shaped projections
shaped
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/733,055
Inventor
Timothy Mark Robinson
Christopher Brian Locke
Aidan Marcus Tout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KCI Licensing Inc
Original Assignee
KCI Licensing Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KCI Licensing Inc filed Critical KCI Licensing Inc
Priority to US16/733,055 priority Critical patent/US20200147280A1/en
Assigned to KCI LICENSING, INC. reassignment KCI LICENSING, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TOUT, AIDAN MARCUS, LOCKE, CHRISTOPHER BRIAN, ROBINSON, TIMOTHY MARK
Publication of US20200147280A1 publication Critical patent/US20200147280A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • A61F13/05Bandages or dressings; Absorbent pads specially adapted for use with sub-pressure or over-pressure therapy, wound drainage or wound irrigation, e.g. for use with negative-pressure wound therapy [NPWT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/0088
    • A61F13/00068
    • A61F13/0216
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H39/00Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
    • A61H39/04Devices for pressing such points, e.g. Shiatsu or Acupressure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61HPHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
    • A61H7/00Devices for suction-kneading massage; Devices for massaging the skin by rubbing or brushing not otherwise provided for
    • A61M1/0023
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91Suction aspects of the dressing
    • A61M1/915Constructional details of the pressure distribution manifold
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00Methods of manufacture, assembly or production

Definitions

  • the present invention relates generally to medical treatment systems and, more particularly, to reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds.
  • Negative pressure therapy has been used to promote healing across a wide range of wound types.
  • an open-cell foam is placed directly into the wound bed.
  • a drape is then used to cover the dressing and seal the wound.
  • the sealing member is then fluidly coupled to a reduced-pressure therapy unit to provide negative pressure, or reduced pressure, to the wound through the foam. While this approach has produced meaningful results, shortcomings and areas of desired of improvement remain.
  • a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue that includes a plurality of shaped projections for creating microstrain within the tissue, a sealing member for placing over the tissue and microstrain-inducing manifold and operable to form a fluid seal over the tissue and microstrain-inducing manifold, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
  • the shaped projections comprise tapered projections.
  • a microstrain-inducing manifold for treating tissue on a patient includes a plurality of shaped projections for creating microstrain within the tissue.
  • the shaped projections comprise tapered projections.
  • a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue.
  • the microstrain-inducing manifold includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue.
  • the shaped projection may be an angled projection.
  • the system further includes a sealing member for placing over the tissue and manifold. The sealing member is operable to form a fluid seal over the tissue and microstrain-inducing manifold.
  • the system further includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
  • a microstrain-inducing manifold for treating tissue on a patient includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue.
  • the shaped projection may be an angled projection.
  • a method for treating tissue on a patient includes placing a microstrain-inducing manifold proximate the tissue of the patient.
  • the microstrain-inducing manifold includes a plurality of shaped projections for creating microstrain within the tissue.
  • the shaped projections may be tapered projections.
  • the method further includes disposing a sealing member over the microstrain-inducing manifold and the patient's epidermis; forming a fluid seal between the sealing member and the patient's epidermis; and providing reduced pressure to the microstrain-inducing manifold whereby the plurality of shaped projections create microstrain within the tissue.
  • FIG. 1 is a schematic, perspective view of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system for treating a wound on a patient shown over a wound;
  • FIG. 2 is a schematic, cross-sectional view of a portion of the system of FIG. 1 taken along line 2 - 2 in FIG. 1 ;
  • FIG. 3A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site, such as a wound, on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
  • FIG. 3B is an enlarged detail of the perspective view of FIG. 3A ;
  • FIG. 3C is a side view of a portion of an interconnected node and shaped projection of the microstrain-inducing manifold shown in FIGS. 3A and 3B ;
  • FIG. 4A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site;
  • FIG. 4B is a schematic, top view of the microstrain-inducing manifold of FIG. 4A ;
  • FIG. 5A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient;
  • FIG. 5B is an enlarged partial view of the microstrain-inducing manifold of FIG. 5A ;
  • FIG. 6A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
  • FIG. 6B is an enlarged partial view of the microstrain-inducing manifold of FIG. 6A ;
  • FIG. 7 is a schematic, side view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold.
  • tissue site 103 may be, for example, a wound 102 , or damaged area of tissue, on a patient.
  • the tissue site 103 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity.
  • the reduced-pressure wound treatment system 100 is shown in the context of the wound 102 , it will be appreciated that the reduced-pressure wound treatment system 100 may be used to treat many different types of tissue sites 103 and wounds including area wounds, incisions, internal wounds, or other tissue sites.
  • the reduced-pressure wound treatment system 100 is shown on the wound 102 , which is through the epidermis 104 , or generally skin, and the dermis 106 and reaching into a hypodermis, or subcutaneous tissue 108 .
  • the reduced-pressure wound treatment system 100 generally includes a sealing member 110 , a microstrain-inducing manifold 112 , and a reduced-pressure subsystem 114 .
  • the microstrain-inducing manifold 112 induces microstrain and may be referred to as a microstrain-inducing manifold.
  • the microstrain-inducing manifold 112 has a first side 113 and a second, patient-facing side 115 .
  • microstrain results from pressure distributed with the microstrain-inducing manifold 112 to a tissue site 103 , such as a wound surface 105 of the wound 102 . It is believed that this action creates areas of cell surface strain, or microdeformation.
  • the cells appear to respond to the strain by expressing special receptors on the surface of the cells and turning on genetic pathways in the cells, which promote healing activities.
  • the healing activities may include increased metabolic activity, stimulation of fibroblast migration, increased cellular proliferation, extra cellular matrix production, and the formation of granulation tissue, as well as a decrease in edema and a subsequent improvement of perfusion at the tissue site 103 .
  • granulation tissue fills the wound 102 and thereby further reduces volume and prepares the wound 102 for final closure by secondary or delayed primary intention.
  • the sealing member 110 is generally formed from a flexible sheet.
  • the sealing member 110 includes a first surface 120 and a patient-facing surface 122 .
  • the sealing member 110 may be sized so that the sealing member 110 overlaps the wound 102 in such a manner that a drape extension 116 extends beyond the peripheral edge of the wound 102 .
  • the sealing member 110 may be formed from any material that provides a fluid seal.
  • fluid seal or “seal,” means a seal adequate to maintain reduced pressure at a desired site, e.g., a tissue site, given the particular reduced-pressure source involved.
  • the sealing member may, for example, be an impermeable or semi-permeable, elastomeric material.
  • “Elastomeric” means having the properties of an elastomer. Elastomeric generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation.
  • elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones.
  • sealing member materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as one available from Avery Dennison, or an incise drape.
  • An attachment member 118 or device may be coupled to the sealing member 110 .
  • the attachment member 118 is operable to removably couple the sealing member 110 to a patient's epidermis 104 .
  • the term “coupled” includes coupling via a separate object and includes direct coupling.
  • the term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material.
  • the term “coupled” may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling.
  • Fluid coupling means that fluid is in communication between the designated parts or locations.
  • the sealing member 110 and attachment member 118 work together to form a fluid seal over the patient's epidermis 104 .
  • the attachment member 118 may be any material suitable to help couple the sealing member 110 to a patient's epidermis 104 .
  • the attachment member 118 may be a pressure-sensitive adhesive, heat-activated adhesive, sealing tape, double-sided sealing tape, paste, hydrocolloid, hydrogel, hooks, sutures, etc.
  • the attachment member 118 is an adhesive layer 119 coupled to the patient-facing surface 122 of the drape extension 116 .
  • the attachment member 118 may span the entire width or a portion of the patient-facing surface 122 of the sealing member 110 .
  • the attachment member 118 may be applied over the entire first surface 120 of the sealing member 110 , or over the first surface of the drape extensions 116 .
  • the microstrain-inducing manifold 112 is typically positioned between the second, patient-facing surface 122 of the sealing member 110 and the tissue site 103 , e.g., the wound 102 .
  • the microstrain-inducing manifold 112 may be sized to approximate the estimated area of the wound 102 , although a larger or smaller size may be used in different applications.
  • the microstrain-inducing manifold 112 includes a plurality of interconnected nodes 124 .
  • the interconnected nodes 124 may have a substantially circular cross-section, but it will be appreciated that the interconnected nodes 124 may have any suitable cross-section including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc.
  • Each interconnected node 124 may include one or more shaped projections 126 .
  • the shaped projections 126 are operable to create microstrain at the cellular level within the tissue site 103 , e.g., the wound 102 . While the illustrative embodiment shows each interconnected node 124 having a plurality of shaped projections 126 , it will be appreciated that some interconnected nodes 124 may be formed to avoid creating microstrains in certain areas. For example, one or more shaped projections 126 may be formed with a lower profile in a certain area or be absent all together in certain areas.
  • an additional manifold with no shaped projections e.g., a smooth, laminar manifold, may be placed between at least a portion of the shaped projections 126 of the microstrain-inducing manifold 112 and a portion of the tissue site 103 to prevent the creation of strain in a certain area. It is believed that avoiding microstrains in certain areas is helpful to overall patient care.
  • microstrain-inducing manifold 112 without projections 126 or that does not create microstrains in certain areas if a portion of the microstrain-inducing manifold 112 will lay on top of a vein, an artery, graft(s), objects used for adjunctive treatment or therapy (e.g., stents), exposed organs (e.g., heart or bowel), etc.
  • objects used for adjunctive treatment or therapy e.g., stents
  • exposed organs e.g., heart or bowel
  • the shaped projections 126 may be substantially the same size. Alternatively, some projections 126 may be larger or smaller than others. In one alternative, some shaped projections 126 may have a larger pitch than others, where “pitch” is defined by the angle 128 between a reference line 127 formed to have a right angle with a longitudinal axis 129 of the shaped projection 126 as shown in cross section in FIG. 3C . Each shaped projection 126 has an outer surface 130 and a base 132 .
  • the shaped projections 126 in the illustrative embodiment are conical in shape, it will be appreciated that the shaped projections 126 may have any suitable shape capable of creating a microstrain within the wound 102 ; for example, the shaped projections 126 may be substantially cube shaped, pyramid shaped, hemispherically shaped, cylindrically shaped, triangularly shaped, cylindrically shaped with a distal recess, tapered, more elaborately shaped, etc.
  • the shaped projections 126 are typically angled or tapered from a thick proximal end to a thin distal end or vice versa.
  • the shaped projections 126 are formed of the same material as the interconnected nodes 124 .
  • the shaped projections 126 may be formed from a different material or the same material type of material with different properties than the interconnected nodes 124 or the other shaped projections 126 . Via material selection, one may control the stiffness of the interconnected nodes 124 such that greater microstrain may be provided in certain areas of the wound 102 versus others.
  • the interconnected nodes 124 , shaped projections 126 , and the microstrain-inducing manifold 112 generally may be formed of a foam material or a non-foam material.
  • the interconnected nodes 124 may be interconnected using a network of connecting members 134 .
  • the network of connecting members 134 may include a plurality of members 136 with each member 136 coupling adjacent interconnected nodes 124 to one another.
  • the members 136 have a substantially circular cross-section; however, it will be appreciated that the members 136 may have any suitable cross-section, including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc.
  • the connecting members 134 may be configured such that the microstrain-inducing manifold 112 behaves anisotropically when subjected to a reduced pressure.
  • the interconnected nodes 124 , connecting members 134 , and shaped projections 126 are arranged such that the microstrain-inducing manifold 112 includes a plurality of flow channels 140 ( FIG. 3B ) or pathways between the interconnected nodes 124 .
  • the flow channels 140 improve distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 112 .
  • the microstrain-inducing manifold 112 is operable to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site 103 .
  • the design of microstrain-inducing manifold 112 helps to avoid painful removal caused by in-growth, i.e., when growth of granulation tissue occurs into a manifold, and allows for easier removal from the tissue site 103 .
  • the microstrain-inducing manifold 112 may be formed from any suitable material.
  • the microstrain-inducing manifold 112 may be formed from an elastomer, a bioabsorbable/biodegradable polymer, etc.
  • the manifold material may itself be, or may be combined with, a radio opaque material or a UV florescent material such that the wound 102 may be scanned with an X-ray or UV light in order to determine whether or not any remnants of the microstrain-inducing manifold 112 remain in the wound 102 after efforts have been made to remove the microstrain-inducing manifold 112 from the wound 102 .
  • the shaped projections 126 may be coated with a drug (e.g., an anticoagulant), an antimicrobial agent (e.g., silver or copper), a hydrophilic material, etc.
  • a drug e.g., an anticoagulant
  • an antimicrobial agent e.g., silver or copper
  • a hydrophilic material e.g., a hydrophilic material
  • the microstrain-inducing manifold 112 may also be formed with additional components, e.g., a delivery tube (not shown), whereby drugs or antimicrobial agents may be delivered to the wound 102 through the microstrain-inducing manifold 112 .
  • the microstrain-inducing manifold 112 may be formed by any suitable process, including, but not limited to, micromolding, injection molding, casting, etc.
  • the shaped projections 126 may be formed to be substantially integral with corresponding interconnected nodes 124 or may be coupled to corresponding interconnected nodes 124 by any suitable technique, including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
  • the microstrain-inducing manifold 112 may include numerous devices for creating point pressure or otherwise inducing microstrain.
  • the microstrain-inducing manifold 112 includes limited contact points with the tissue site 103 . The contact points contribute to the inducement of microstrain at the tissue site 103 .
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 40 percent of the surface area X (40% X).
  • projection surface area means the area that a general projection of an item would make on a flat surface.
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 30 percent of the surface area X (30% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 20 percent of the surface area X (20% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 10 percent of the surface area X (10% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 5 percent of the surface area X (5% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 2 percent of the surface area X (2% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 1 percent of the surface area X (1% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.5 percent of the surface area X (0.5% X).
  • the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm 2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.2 percent of the surface area X (0.2% X).
  • the microstrain-inducing manifold 112 adjacent to tissue site 103 103 may cover the wound surface 105 , and may have a projection surface area X, and yet the portion of microstrain-inducing manifold 112 directly impinging on the wound surface 105 may only be 0.2 percent of X.
  • the impinging portion may only be a portion of an outer surface 130 of each of the plurality of shaped projections 126 .
  • the microstrain-inducing manifold 112 may be disposed proximate the wound 102 such that the interconnected nodes 124 engage the wound surface 105 .
  • the microstrain-inducing manifolds 112 are stacked on top of one another to substantially fill the wound 102 .
  • a single microstrain-inducing manifold 112 may be employed or a multi-layer microstrain-inducing manifold may also be formed and used.
  • the microstrain-inducing manifold 112 may be formed from a single interconnected node 124 with a shaped projection 126 ; multiple independent interconnected nodes 124 with shaped projections 126 ; or a group of interconnected nodes 124 , which include shaped projections 126 , that are interconnected with the connecting members 134 .
  • a single microstrain-inducing manifold 112 may be rolled up or folded over itself in order to fill the wound 102 . Furthermore, it will be appreciated that a single microstrain-inducing manifold 112 may be loaded into the wound 102 and an additional manifold placed atop the manifold 112 . Examples of additional manifolds that may be placed atop the microstrain-inducing manifold 112 include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam such as open-cell foam, porous tissue collections, and liquids, gels and foams that include or cure to include flow channels.
  • the reduced-pressure subsystem 114 includes a reduced-pressure source 142 , which may take many different forms.
  • the reduced-pressure source 142 provides reduced pressure as a part of the reduced-pressure wound treatment system 100 .
  • reduced pressure generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Reduced pressure may initially generate fluid flow in the microstrain-inducing manifold 112 , a conduit 150 , and proximate the tissue site 103 .
  • the reduced pressure delivered may be static or dynamic (patterned or random) and may be delivered continuously or intermittently.
  • the reduced-pressure subsystem 114 provides reduced pressure.
  • the reduced-pressure subsystem 114 includes a reduced-pressure source 142 that may be any source of a reduced pressure, such a vacuum pump, wall suction, etc. While the amount and nature of reduced pressure applied to a tissue site will typically vary according to the application, the reduced pressure will typically be between ⁇ 5 mm Hg and ⁇ 500 mm Hg. Pressure may be applied to the microstrain-inducing manifold 112 in other ways as well; for example, a pressure wrap may be used.
  • the reduced-pressure source 142 is shown having a battery compartment 144 and a canister region 146 with windows 148 providing a visual indication of the level of fluid within canister 146 .
  • An interposed membrane filter such as hydrophobic or oleophobic filter, may be interspersed between the conduit 150 , or tubing, and the reduced-pressure source 142 .
  • the reduced pressure supplied by the reduced-pressure source 142 is delivered through the conduit 150 to a reduced-pressure interface 152 , which may be an elbow port 154 .
  • the port 154 is a TRAC® technology port available from Kinetic Concepts, Inc. of San Antonio, Texas.
  • the reduced-pressure interface 152 allows the reduced pressure to be delivered to the sealing member 110 and realized within an interior portion of sealing member 110 as well as the microstrain-inducing manifold 112 .
  • the port 154 extends through the sealing member 110 to the microstrain-inducing manifold 112 .
  • the reduced-pressure wound treatment system 100 may be applied to a patient's epidermis 104 over the tissue site 103 , e.g., wound 102 .
  • the microstrain-inducing manifold 112 may be disposed proximate the tissue site 103 , e.g., disposed within the wound 102 , or may overlay a portion of the wound 102 .
  • the sealing member 110 may be placed over the top of the microstrain-inducing manifold 112 such that drape extensions 116 extend beyond the periphery of the wound 102 .
  • the drape extensions 116 are secured to the patient's epidermis 104 (or a gasket member, such an additional piece of over drape surrounding the wound edges) by the attachment member 118 in order to form a fluid seal over the wound 102 .
  • a fluid seal with the patient's epidermis shall be deemed to also include forming a seal with a gasket proximate the wound 102 .
  • the reduced-pressure interface 152 is applied, if not already installed, and the conduit 150 fluidly coupled at one end to the reduced-pressure interface 152 .
  • the other end of the conduit 150 is fluidly coupled to the reduced-pressure source 142 .
  • the reduced-pressure source 142 may be activated such that reduced pressure is delivered to the sealing member 110 and microstrain-inducing manifold 112 .
  • the reduced pressure provides reduced-pressure treatment to the tissue site 103 , removes fluids, and may force the shaped projections 126 of the microstrain-inducing manifold 112 against the wound 102 such that they create a microstrain at the cellular level within the wound 102 .
  • the microstrain may promote cellular proliferation, formation of granular tissue, and other beneficial effects.
  • the microstrain-inducing manifold 112 may be placed proximate the tissue site 103 and then pressure may be applied by using a wrap over the microstrain-inducing manifold 112 or other source of pressure.
  • microstrain-inducing manifold 212 for use as part of a reduced-pressure wound treatment, such as the reduced-pressure wound treatment system 100 in FIG. 1 .
  • the microstrain-inducing manifold 212 includes interconnected nodes 224 , which include shaped projections 226 extending from the interconnected nodes 224 .
  • the shaped projections 226 are conical in shape; however, it will be appreciated that the shaped projections 226 may be any suitable shape capable of creating microstrain within a wound as previously discussed.
  • each interconnected node 224 of the illustrative embodiment includes two projections 226 (one directed up and one directed down for the orientation shown in FIG. 4A ), it will be appreciated that any number of projections 224 may extend from each interconnected node 224 or that some of the interconnected nodes 224 may have no projections 224 . Also, in the illustrative embodiment, each projection 226 extends substantially normal from a corresponding interconnected node 224 , but it will be appreciated that each projection 226 may extend from the corresponding interconnected node 224 at any angle.
  • the interconnected nodes 224 are spaced apart and interconnected by a network of connecting members 234 as clearly shown in FIG. 4B .
  • the network of connecting members 234 includes a plurality of curved members 236 .
  • a plurality of flow channels 240 are formed between the interconnected nodes 224 and members 236 .
  • the members 236 have curved surfaces 290 that are curved in a cooperative manner with one another or with the radius of one or more corresponding interconnected nodes 224 such that when the microstrain-inducing manifold 212 is subjected to a reduced pressure, the microstrain-inducing manifold 212 collapses (partially or fully) in two directions (e.g., along the x-axis 286 and y-axis 288 ) but not at all or to a lesser extent in a third direction (e.g., the z-axis 284 ).
  • each curved surface 290 of each member 236 abuts or approaches a curved surface 290 of an adjacent member 236 or at least one corresponding interconnected node 224 . This may be particularly advantageous if the reduced-pressure wound treatment system is configured to assist in drawing the wound together during reduced pressure therapy.
  • a manifold structure 412 which is a form of a microstrain-inducing manifold.
  • the manifold structure 412 is for use with a reduced-pressure wound treatment system, such as the reduced-pressure wound treatment system 100 of FIG. 1 , is shown.
  • the manifold structure 412 includes one or more longitudinal members 456 .
  • the longitudinal members 456 may be coupled in a spaced relationship by lateral connecting members 460 .
  • the lateral connecting members 460 may be coupled to the longitudinal members 456 .
  • the longitudinal members 456 and lateral connecting members 460 are shown with circular cross-sections, but it should be appreciated that the longitudinal members 456 and lateral connecting members 460 may have any suitable cross-sectional shape. While reference is made to longitudinal and lateral members, the members 456 , 460 need not be orthogonal but may have other relative angles.
  • Each longitudinal member 456 of the manifold structure 412 includes one or more shaped projections 426 for creating a microstrain within a wound.
  • the longitudinal members 456 and shaped projections 426 are arranged such that the manifold structure 412 includes a plurality of flow channels 440 or pathways between adjacent longitudinal members 456 or between projections 426 .
  • the flow channels 440 facilitate distribution of fluids provided to and removed from the area of tissue around the manifold structure 412 .
  • any combination of longitudinal members 456 and lateral members 460 may be used.
  • the manifold structure 412 may be formed by a longitudinally connected group of longitudinal members 456 with projections 426 . There are eight such longitudinal groups shown in FIG.
  • lateral connecting members 460 may be omitted in some embodiments.
  • lateral connecting members 460 may be distributed at various locations between the longitudinal members 456 .
  • each shaped projection 426 projects substantially normal from the corresponding longitudinal member 456 .
  • “normal” is a vector which perpendicular to that surface. For a non-flat surface, the normal vector may be taken at a point and is the same as a normal to the tangent plane at that point. It should be appreciated, however, that each shaped projection 426 may project at any angle relative to the corresponding longitudinal member 456 .
  • Each shaped projection 426 may include a columnar body 427 , which has a first outer diameter (D 1 ), and an enlarged member 429 , which has a second outer diameter (D 2 ). Each enlarged member 429 is positioned at the distal end of an associated columnar body 427 .
  • Each columnar body 429 may have any shape, e.g., the cross-section may be a circular, square, elliptical, irregular, etc., and may vary along its longitudinal dimension.
  • the enlarged member 429 may be a spherical member as shown or may take any other shape, such as rounded cylindrical member, a cubical member, or an irregular shape.
  • the second outer diameter (D 2 ) of the enlarged member 429 is greater than the first outer diameter (D 1 ) of the columnar body 427 , i.e., D 2 >D 1 .
  • the shaped projections 426 may be considered to be tapered from a larger distal end to a smaller proximal end.
  • Each shaped projection 426 may have any suitable shape capable of creating a microstrain within the wound when the shaped projection 426 impinges upon the wound. Additionally, in the illustrative embodiment, the shaped projections 426 have substantially equal heights, but it will be appreciated that the shaped projections 426 may have varying heights along each longitudinal member 456 or among the plurality of longitudinal members 456 . Also, it will be appreciated that certain portions of certain longitudinal members 456 may not have shaped projections 426 such that microstrain is not provided to certain areas within the wound. As with the microstrain-inducing manifolds previously discussed, the manifold structure 412 may be formed using any suitable process, including, but not limited to, micromolding, injection molding, casting, etc.
  • the shaped projections 426 may be formed to be substantially integral with corresponding longitudinal members 456 or may be coupled to corresponding longitudinal members 456 by any suitable technique including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
  • the manifold structure 412 is placed proximate the tissue site, e.g., wound, and a sealing member is deployed over the manifold structure 412 and tissue site. Reduced pressure may then be applied or alternatively a direct pressure may be applied.
  • the manifold structure 412 may behave anisotropically.
  • the longitudinal members 456 may move laterally towards each other. Each longitudinal member 456 move closer to an adjacent longitudinal member 456 than the adjacent longitudinal members 456 were prior to the introduction of the reduced pressure.
  • the manifold structure 412 does not substantially contract in a direction substantially parallel to the longitudinal members 456 .
  • the manifold structure 412 may deform more in a direction substantially perpendicular to the longitudinal members 456 (as illustrated by arrows 458 in FIG. 5A ) without a proportional deformation in the direction parallel with the longitudinal members 456 .
  • the deformation is typically within the same plane. This may be advantageous if the system employs other components, such as an anisotropic drape or another manifold, for drawing the wound together during reduced pressure therapy wherein the illustrative manifold structure 412 contracts in a manner complimentary therewith. If spaced lateral connecting members 460 are used in sufficient number, very little contraction may take place.
  • the manifold structure 412 is configured such that some longitudinal members 456 are arranged substantially perpendicular to other longitudinal members 456 whereby the manifold structure 412 partially contracts, or contracts in a more limited manner, in two directions within the same plane when subjected to a reduced pressure.
  • FIGS. 6A and 6B another illustrative, non-limiting embodiment of a microstrain-inducing manifold 512 for use with a reduced-pressure wound treatment system, such as a reduced-pressure wound treatment system 100 ( FIG. 1 ), is shown.
  • the microstrain-inducing manifold 512 includes a mat 558 , or base, from which a plurality of shaped projections 526 extend.
  • the mat 558 has a first side 513 and a second, patient-facing side 515 .
  • the shaped projections 526 are tapered and in particular are substantially conical in shape, but it will be appreciated that the projections 526 may have any suitable shape capable of creating microstrain within the wound.
  • the projections 526 may extend from the mat 558 at any suitable angle.
  • the projections 526 have substantially equal heights, but the mat 558 may include projections 526 of varying heights. Portions of the mat 558 may not have any projections such that microstrain is not provided to certain areas within the wound. Additionally, the stiffness of the shaped projections 526 and pitch of the shaped projections 526 may vary along the mat 558 such that the microstrain created by the projections 526 may be greater in certain areas of the wound versus other areas.
  • the shaped projections 526 may be formed as integral portions of the mat 558 or coupled to the mat 558 by any suitable techniques, including but not limited to mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
  • the mat 558 may also includes a plurality of apertures 560 ( FIG. 6B ) disposed between the projections 526 to improve the distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 512 .
  • the shaped projections 526 may be formed from a modified honey on the mat 558 .
  • the honey may be modified so that it is solid or partially solid and retains its shape for at least a certain amount of time whilst engaging the wound.
  • the honey may act as an antimicrobial agent and may be absorbed by the patient after a period of time. Other dissolvable substances may be used as well.
  • the microstrain-inducing manifold 512 is typically placed proximate the tissue site with the second, patient-facing side 515 facing the patient and covered with a sealing member. Reduced pressure is then delivered to the microstrain-inducing manifold 512 . When subjected to a reduced pressure, the microstrain-inducing manifold 512 impinges on the wound whereby the shaped projections 526 create microstrain within the wound. Additionally, exudate and other fluids pass through the mat 558 via the apertures 560 . Also, in some instances, it may be desirable to avoid increasing microstrain within the wound via the shaped projections 526 .
  • the microstrain-inducing manifold 512 may be inverted such that the first side 513 of the mat 558 is placed against the wound and the shaped projections 526 extend towards the sealing member (not shown).
  • the microstrain-inducing manifold 512 may assist in perfusion and fluid removal (via the apertures 560 ) without also increasing microstrain within the wound via the shaped projections 526 .
  • a microstrain-inducing manifold member 624 for use with a reduced-pressure wound treatment system such as the reduced-pressure wound treatment system 100 in FIG. 1 , is shown.
  • a microstrain-inducing manifold may be formed by a plurality of microstrain-inducing manifolds 624 .
  • Each microstrain-inducing manifold member 624 has one or more shaped projections 626 extending from a surface 631 .
  • the microstrain-inducing manifold members 624 are not interconnected by a network of connecting members.
  • a plurality of microstrain-inducing manifold members 624 may be poured into a wound whereby they work together to form the microstrain-inducing manifold in the wound (in situ) and whereby the shaped projections 626 of the microstrain-inducing manifold members 624 contact the wound to create microstrain therein.
  • the plurality of microstrain-inducing manifold members 624 may fill the entire wound.
  • the plurality of microstrain-inducing manifold members 624 may partially fill the wound, and, optionally, an alternative manifold may be placed atop the microstrain-inducing manifold members 624 to fill the wound.
  • the microstrain-inducing manifold members 624 may have a coating of material that allows the microstrain-inducing manifold members 624 to fuse or sinter in situ to one another and form a single, integral manifold.
  • coatings include the following: any water soluble, swellable, or softenable material, including polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrrolidone and its copolymers, polyethylene oxide and its copolymers, polypropylene oxide and its copolymers, hydroxyl, carboxyl, and sulphonyl containing polymers (e.g., hydroxyl ethyl acrylate, carboxyl methyl cellulose, acrylamido methyl propane sulphonic acid and its salts), alginates, gums (e.g. xanthan and guar), other hydrogels and hydrocolloids.
  • polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrroli

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)

Abstract

Microstrain-inducing manifolds, systems, and methods are presented that involve microstrain-inducing manifolds that include a plurality of shaped projections for creating microstrain. The shaped projections may be tapered projections. A system may include a sealing member for placing over the tissue site, a microstrain-inducing manifold, and a reduced-pressure subsystem that delivers reduced pressure to the sealing member. The reduced pressure causes the shaped projections to create microstrain at the tissue site. Other methods, apparatuses, and systems are also presented.

Description

    RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 15/448,793, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing Microstrain-Inducing Manifolds,” filed Mar. 3, 2017, which is a continuation of U.S. patent application Ser. No. 13/963,809, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Aug. 9, 2013, which is a continuation of U.S. patent application Ser. No. 12/639,253, now U.S. Pat. No. 9,622,915, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Dec. 16, 2009, now U.S. Pat. No. 8,529,528, which claims the benefit, under 35 U.S.C. § 119(e), of the filing of U.S. Provisional Patent Application No. 61/140,662, entitled “Reduced-Pressure Wound Treatment Systems and Methods Employing a Microstrain-Inducing Manifold,” filed Dec. 24, 2008, which is incorporated herein by reference for all purposes. U.S. patent application Ser. No. 12/639,253, filed Dec. 12, 2009, now U.S. Pat. No. 8,529,528, is a previous co-pending application of U.S. patent application Ser. No. 12/639,288, filed Dec. 16, 2009, now U.S. Pat. No. 8,708,984, entitled, “Reduced-Pressure Wound Treatment Systems and Methods Employing Manifold Structures.”
  • BACKGROUND
  • The present invention relates generally to medical treatment systems and, more particularly, to reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds.
  • Clinical studies and practice have shown that providing a reduced pressure in proximity to a tissue site augments and accelerates the growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but application of reduced pressure has been particularly successful in treating wounds. This treatment (frequently referred to in the medical community as “negative pressure wound therapy,” “NPWT,” “reduced pressure therapy,” or “vacuum therapy”) provides a number of benefits, which may include faster healing and increased formulation of granulation tissue.
  • Negative pressure therapy, or reduced-pressure therapy, has been used to promote healing across a wide range of wound types. Typically, an open-cell foam is placed directly into the wound bed. A drape is then used to cover the dressing and seal the wound. The sealing member is then fluidly coupled to a reduced-pressure therapy unit to provide negative pressure, or reduced pressure, to the wound through the foam. While this approach has produced meaningful results, shortcomings and areas of desired of improvement remain.
  • BRIEF SUMMARY
  • Shortcomings with wound care systems and methods are addressed by the illustrative embodiments herein. According to one illustrative embodiment, a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue that includes a plurality of shaped projections for creating microstrain within the tissue, a sealing member for placing over the tissue and microstrain-inducing manifold and operable to form a fluid seal over the tissue and microstrain-inducing manifold, and a reduced-pressure subsystem for delivering a reduced pressure to the sealing member. The shaped projections comprise tapered projections.
  • According to another illustrative embodiment, a microstrain-inducing manifold for treating tissue on a patient includes a plurality of shaped projections for creating microstrain within the tissue. The shaped projections comprise tapered projections.
  • According to another illustrative embodiment, a reduced-pressure wound treatment system for treating tissue on a patient includes a microstrain-inducing manifold for disposing proximate the tissue. The microstrain-inducing manifold includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue. The shaped projection may be an angled projection. The system further includes a sealing member for placing over the tissue and manifold. The sealing member is operable to form a fluid seal over the tissue and microstrain-inducing manifold. The system further includes a reduced-pressure subsystem for delivering a reduced pressure to the sealing member.
  • According to another illustrative embodiment, a microstrain-inducing manifold for treating tissue on a patient includes a plurality of interconnected nodes. At least one of the interconnected nodes includes at least one shaped projection for creating microstrain within the tissue. The shaped projection may be an angled projection.
  • According to another illustrative embodiment, a method for treating tissue on a patient includes placing a microstrain-inducing manifold proximate the tissue of the patient. The microstrain-inducing manifold includes a plurality of shaped projections for creating microstrain within the tissue. The shaped projections may be tapered projections. The method further includes disposing a sealing member over the microstrain-inducing manifold and the patient's epidermis; forming a fluid seal between the sealing member and the patient's epidermis; and providing reduced pressure to the microstrain-inducing manifold whereby the plurality of shaped projections create microstrain within the tissue.
  • Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • A more complete understanding of the present invention may be obtained by reference to the following Detailed Description when taken in conjunction with the accompanying Drawings wherein:
  • FIG. 1 is a schematic, perspective view of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system for treating a wound on a patient shown over a wound;
  • FIG. 2 is a schematic, cross-sectional view of a portion of the system of FIG. 1 taken along line 2-2 in FIG. 1;
  • FIG. 3A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site, such as a wound, on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
  • FIG. 3B is an enlarged detail of the perspective view of FIG. 3A;
  • FIG. 3C is a side view of a portion of an interconnected node and shaped projection of the microstrain-inducing manifold shown in FIGS. 3A and 3B;
  • FIG. 4A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a tissue site;
  • FIG. 4B is a schematic, top view of the microstrain-inducing manifold of FIG. 4A;
  • FIG. 5A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient;
  • FIG. 5B is an enlarged partial view of the microstrain-inducing manifold of FIG. 5A;
  • FIG. 6A is a schematic, perspective view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold for use in treating a wound on a patient as part of an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system;
  • FIG. 6B is an enlarged partial view of the microstrain-inducing manifold of FIG. 6A; and
  • FIG. 7 is a schematic, side view of an illustrative, non-limiting embodiment of a microstrain-inducing manifold.
  • DETAILED DESCRIPTION
  • In the following detailed description of the preferred embodiments, reference is made to the accompanying drawings that form a part hereof, and in which is shown, by way of illustration, specific embodiments in which the invention may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is understood that other embodiments may be utilized and that logical structural, mechanical, electrical, and chemical changes may be made without departing from the spirit or scope of the invention. To avoid detail not necessary to enable those skilled in the art to practice the invention, the description may omit certain information known to those skilled in the art. The following detailed description is, therefore, not to be taken in a limiting sense, and the scope of the present invention is defined only by the appended claims.
  • Referring now primarily to FIGS. 1-3B, an illustrative, non-limiting embodiment of a reduced-pressure wound treatment system 100 for treating a tissue site 103 on a patient is presented. The tissue site 103 may be, for example, a wound 102, or damaged area of tissue, on a patient. The tissue site 103 may be the bodily tissue of any human, animal, or other organism, including bone tissue, adipose tissue, muscle tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, ligaments, or any other tissue. Unless otherwise indicated, as used herein, “or” does not require mutual exclusivity. While the reduced-pressure wound treatment system 100 is shown in the context of the wound 102, it will be appreciated that the reduced-pressure wound treatment system 100 may be used to treat many different types of tissue sites 103 and wounds including area wounds, incisions, internal wounds, or other tissue sites. The reduced-pressure wound treatment system 100 is shown on the wound 102, which is through the epidermis 104, or generally skin, and the dermis 106 and reaching into a hypodermis, or subcutaneous tissue 108.
  • The reduced-pressure wound treatment system 100 generally includes a sealing member 110, a microstrain-inducing manifold 112, and a reduced-pressure subsystem 114. As will be described further below, in operation the microstrain-inducing manifold 112 induces microstrain and may be referred to as a microstrain-inducing manifold. The microstrain-inducing manifold 112 has a first side 113 and a second, patient-facing side 115.
  • Among the numerous benefits of the reduced-pressure wound treatment system 100 is the biological response initiated by microstrain within the wound 102. Microstrain results from pressure distributed with the microstrain-inducing manifold 112 to a tissue site 103, such as a wound surface 105 of the wound 102. It is believed that this action creates areas of cell surface strain, or microdeformation. The cells appear to respond to the strain by expressing special receptors on the surface of the cells and turning on genetic pathways in the cells, which promote healing activities. The healing activities may include increased metabolic activity, stimulation of fibroblast migration, increased cellular proliferation, extra cellular matrix production, and the formation of granulation tissue, as well as a decrease in edema and a subsequent improvement of perfusion at the tissue site 103. With respect to the wound 102, over time, granulation tissue fills the wound 102 and thereby further reduces volume and prepares the wound 102 for final closure by secondary or delayed primary intention.
  • The sealing member 110 is generally formed from a flexible sheet. The sealing member 110 includes a first surface 120 and a patient-facing surface 122. The sealing member 110 may be sized so that the sealing member 110 overlaps the wound 102 in such a manner that a drape extension 116 extends beyond the peripheral edge of the wound 102.
  • The sealing member 110 may be formed from any material that provides a fluid seal. As used herein, “fluid seal,” or “seal,” means a seal adequate to maintain reduced pressure at a desired site, e.g., a tissue site, given the particular reduced-pressure source involved. The sealing member may, for example, be an impermeable or semi-permeable, elastomeric material. “Elastomeric” means having the properties of an elastomer. Elastomeric generally refers to a polymeric material that has rubber-like properties. More specifically, most elastomers have ultimate elongations greater than 100% and a significant amount of resilience. The resilience of a material refers to the material's ability to recover from an elastic deformation. Examples of elastomers may include, but are not limited to, natural rubbers, polyisoprene, styrene butadiene rubber, chloroprene rubber, polybutadiene, nitrile rubber, butyl rubber, ethylene propylene rubber, ethylene propylene diene monomer, chlorosulfonated polyethylene, polysulfide rubber, polyurethane, EVA film, co-polyester, and silicones. Specific examples of sealing member materials include a silicone drape, 3M Tegaderm® drape, acrylic drape such as one available from Avery Dennison, or an incise drape.
  • An attachment member 118 or device may be coupled to the sealing member 110. The attachment member 118 is operable to removably couple the sealing member 110 to a patient's epidermis 104. As used herein, the term “coupled” includes coupling via a separate object and includes direct coupling. The term “coupled” also encompasses two or more components that are continuous with one another by virtue of each of the components being formed from the same piece of material. Also, the term “coupled” may include chemical, such as via a chemical bond, mechanical, thermal, or electrical coupling. Fluid coupling means that fluid is in communication between the designated parts or locations. The sealing member 110 and attachment member 118 work together to form a fluid seal over the patient's epidermis 104. The attachment member 118 may be any material suitable to help couple the sealing member 110 to a patient's epidermis 104. For example, the attachment member 118 may be a pressure-sensitive adhesive, heat-activated adhesive, sealing tape, double-sided sealing tape, paste, hydrocolloid, hydrogel, hooks, sutures, etc.
  • In the illustrative embodiment, the attachment member 118 is an adhesive layer 119 coupled to the patient-facing surface 122 of the drape extension 116. The attachment member 118 may span the entire width or a portion of the patient-facing surface 122 of the sealing member 110. Alternatively, in the case of sealing tape, the attachment member 118 may be applied over the entire first surface 120 of the sealing member 110, or over the first surface of the drape extensions 116.
  • The microstrain-inducing manifold 112 is typically positioned between the second, patient-facing surface 122 of the sealing member 110 and the tissue site 103, e.g., the wound 102. The microstrain-inducing manifold 112 may be sized to approximate the estimated area of the wound 102, although a larger or smaller size may be used in different applications. In the illustrative embodiment, the microstrain-inducing manifold 112 includes a plurality of interconnected nodes 124. The interconnected nodes 124 may have a substantially circular cross-section, but it will be appreciated that the interconnected nodes 124 may have any suitable cross-section including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc.
  • Each interconnected node 124 may include one or more shaped projections 126. The shaped projections 126 are operable to create microstrain at the cellular level within the tissue site 103, e.g., the wound 102. While the illustrative embodiment shows each interconnected node 124 having a plurality of shaped projections 126, it will be appreciated that some interconnected nodes 124 may be formed to avoid creating microstrains in certain areas. For example, one or more shaped projections 126 may be formed with a lower profile in a certain area or be absent all together in certain areas. Moreover, an additional manifold with no shaped projections, e.g., a smooth, laminar manifold, may be placed between at least a portion of the shaped projections 126 of the microstrain-inducing manifold 112 and a portion of the tissue site 103 to prevent the creation of strain in a certain area. It is believed that avoiding microstrains in certain areas is helpful to overall patient care. For example, it may be desirable to have a microstrain-inducing manifold 112 without projections 126 or that does not create microstrains in certain areas if a portion of the microstrain-inducing manifold 112 will lay on top of a vein, an artery, graft(s), objects used for adjunctive treatment or therapy (e.g., stents), exposed organs (e.g., heart or bowel), etc.
  • The shaped projections 126 may be substantially the same size. Alternatively, some projections 126 may be larger or smaller than others. In one alternative, some shaped projections 126 may have a larger pitch than others, where “pitch” is defined by the angle 128 between a reference line 127 formed to have a right angle with a longitudinal axis 129 of the shaped projection 126 as shown in cross section in FIG. 3C. Each shaped projection 126 has an outer surface 130 and a base 132. While the shaped projections 126 in the illustrative embodiment are conical in shape, it will be appreciated that the shaped projections 126 may have any suitable shape capable of creating a microstrain within the wound 102; for example, the shaped projections 126 may be substantially cube shaped, pyramid shaped, hemispherically shaped, cylindrically shaped, triangularly shaped, cylindrically shaped with a distal recess, tapered, more elaborately shaped, etc. The shaped projections 126 are typically angled or tapered from a thick proximal end to a thin distal end or vice versa. In one embodiment, the shaped projections 126 are formed of the same material as the interconnected nodes 124. Alternatively, at least some of the shaped projections 126 may be formed from a different material or the same material type of material with different properties than the interconnected nodes 124 or the other shaped projections 126. Via material selection, one may control the stiffness of the interconnected nodes 124 such that greater microstrain may be provided in certain areas of the wound 102 versus others. The interconnected nodes 124, shaped projections 126, and the microstrain-inducing manifold 112 generally may be formed of a foam material or a non-foam material.
  • The interconnected nodes 124 may be interconnected using a network of connecting members 134. For example, the network of connecting members 134 may include a plurality of members 136 with each member 136 coupling adjacent interconnected nodes 124 to one another. In the illustrative embodiment, the members 136 have a substantially circular cross-section; however, it will be appreciated that the members 136 may have any suitable cross-section, including, but not limited to, triangular, square, rectangular, hexagonal, octagonal, elliptical, etc. In addition, as will be discussed below, the connecting members 134 may be configured such that the microstrain-inducing manifold 112 behaves anisotropically when subjected to a reduced pressure.
  • The interconnected nodes 124, connecting members 134, and shaped projections 126 are arranged such that the microstrain-inducing manifold 112 includes a plurality of flow channels 140 (FIG. 3B) or pathways between the interconnected nodes 124. The flow channels 140 improve distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 112. Thus, the microstrain-inducing manifold 112 is operable to assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site 103. Moreover, the design of microstrain-inducing manifold 112 helps to avoid painful removal caused by in-growth, i.e., when growth of granulation tissue occurs into a manifold, and allows for easier removal from the tissue site 103.
  • The microstrain-inducing manifold 112 may be formed from any suitable material. By way of example only, and without limitation, the microstrain-inducing manifold 112 may be formed from an elastomer, a bioabsorbable/biodegradable polymer, etc. In addition, the manifold material may itself be, or may be combined with, a radio opaque material or a UV florescent material such that the wound 102 may be scanned with an X-ray or UV light in order to determine whether or not any remnants of the microstrain-inducing manifold 112 remain in the wound 102 after efforts have been made to remove the microstrain-inducing manifold 112 from the wound 102. Additionally, the shaped projections 126, or microstrain-inducing manifold 112 as a whole, may be coated with a drug (e.g., an anticoagulant), an antimicrobial agent (e.g., silver or copper), a hydrophilic material, etc. Optionally, the microstrain-inducing manifold 112 may also be formed with additional components, e.g., a delivery tube (not shown), whereby drugs or antimicrobial agents may be delivered to the wound 102 through the microstrain-inducing manifold 112.
  • The microstrain-inducing manifold 112 may be formed by any suitable process, including, but not limited to, micromolding, injection molding, casting, etc. The shaped projections 126 may be formed to be substantially integral with corresponding interconnected nodes 124 or may be coupled to corresponding interconnected nodes 124 by any suitable technique, including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
  • The microstrain-inducing manifold 112 may include numerous devices for creating point pressure or otherwise inducing microstrain. In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 includes limited contact points with the tissue site 103. The contact points contribute to the inducement of microstrain at the tissue site 103. Thus, in one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 40 percent of the surface area X (40% X). As used herein, “projection surface area” means the area that a general projection of an item would make on a flat surface.
  • In another illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 30 percent of the surface area X (30% X). In another illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 20 percent of the surface area X (20% X). In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 10 percent of the surface area X (10% X). In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 5 percent of the surface area X (5% X).
  • In still another illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 2 percent of the surface area X (2% X). In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 1 percent of the surface area X (1% X). In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.5 percent of the surface area X (0.5% X).
  • In one illustrative, non-limiting embodiment, the microstrain-inducing manifold 112 adjacent the tissue site 103 may have a projection surface area of X cm2 associated with the second, patient-facing side, and yet the portion of the microstrain-inducing manifold 112 directly impinging on the tissue site 103 may be less than 0.2 percent of the surface area X (0.2% X). Referring to FIG. 2, the microstrain-inducing manifold 112 adjacent to tissue site 103 103, e.g., wound surface 105, may cover the wound surface 105, and may have a projection surface area X, and yet the portion of microstrain-inducing manifold 112 directly impinging on the wound surface 105 may only be 0.2 percent of X. Referring to FIG. 3C, it should be understood that the impinging portion may only be a portion of an outer surface 130 of each of the plurality of shaped projections 126.
  • The microstrain-inducing manifold 112 may be disposed proximate the wound 102 such that the interconnected nodes 124 engage the wound surface 105. In one illustrative embodiment, the microstrain-inducing manifolds 112 are stacked on top of one another to substantially fill the wound 102. However, it will be appreciated that a single microstrain-inducing manifold 112 may be employed or a multi-layer microstrain-inducing manifold may also be formed and used. The microstrain-inducing manifold 112 may be formed from a single interconnected node 124 with a shaped projection 126; multiple independent interconnected nodes 124 with shaped projections 126; or a group of interconnected nodes 124, which include shaped projections 126, that are interconnected with the connecting members 134.
  • It will also be appreciated that a single microstrain-inducing manifold 112 may be rolled up or folded over itself in order to fill the wound 102. Furthermore, it will be appreciated that a single microstrain-inducing manifold 112 may be loaded into the wound 102 and an additional manifold placed atop the manifold 112. Examples of additional manifolds that may be placed atop the microstrain-inducing manifold 112 include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam such as open-cell foam, porous tissue collections, and liquids, gels and foams that include or cure to include flow channels.
  • Referring again to FIG. 1, the reduced-pressure subsystem 114 includes a reduced-pressure source 142, which may take many different forms. The reduced-pressure source 142 provides reduced pressure as a part of the reduced-pressure wound treatment system 100. As used herein, “reduced pressure” generally refers to a pressure less than the ambient pressure at a tissue site that is being subjected to treatment. In most cases, this reduced pressure will be less than the atmospheric pressure at which the patient is located. Alternatively, the reduced pressure may be less than a hydrostatic pressure at the tissue site. Reduced pressure may initially generate fluid flow in the microstrain-inducing manifold 112, a conduit 150, and proximate the tissue site 103. As the hydrostatic pressure around the tissue site 103 approaches the desired reduced pressure, the flow may subside, and the reduced pressure may be maintained. Unless otherwise indicated, values of pressure stated herein are gauge pressures. The reduced pressure delivered may be static or dynamic (patterned or random) and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to the tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, an increase in reduced pressure or vacuum pressure typically refers to a relative reduction in absolute pressure.
  • The reduced-pressure subsystem 114 provides reduced pressure. The reduced-pressure subsystem 114 includes a reduced-pressure source 142 that may be any source of a reduced pressure, such a vacuum pump, wall suction, etc. While the amount and nature of reduced pressure applied to a tissue site will typically vary according to the application, the reduced pressure will typically be between −5 mm Hg and −500 mm Hg. Pressure may be applied to the microstrain-inducing manifold 112 in other ways as well; for example, a pressure wrap may be used.
  • In the illustrative embodiment of FIG. 1, the reduced-pressure source 142 is shown having a battery compartment 144 and a canister region 146 with windows 148 providing a visual indication of the level of fluid within canister 146. An interposed membrane filter, such as hydrophobic or oleophobic filter, may be interspersed between the conduit 150, or tubing, and the reduced-pressure source 142.
  • The reduced pressure supplied by the reduced-pressure source 142 is delivered through the conduit 150 to a reduced-pressure interface 152, which may be an elbow port 154. In one illustrative embodiment, the port 154 is a TRAC® technology port available from Kinetic Concepts, Inc. of San Antonio, Texas. The reduced-pressure interface 152 allows the reduced pressure to be delivered to the sealing member 110 and realized within an interior portion of sealing member 110 as well as the microstrain-inducing manifold 112. In this illustrative embodiment, the port 154 extends through the sealing member 110 to the microstrain-inducing manifold 112.
  • In use, the reduced-pressure wound treatment system 100 may be applied to a patient's epidermis 104 over the tissue site 103, e.g., wound 102. The microstrain-inducing manifold 112 may be disposed proximate the tissue site 103, e.g., disposed within the wound 102, or may overlay a portion of the wound 102. The sealing member 110 may be placed over the top of the microstrain-inducing manifold 112 such that drape extensions 116 extend beyond the periphery of the wound 102. The drape extensions 116 are secured to the patient's epidermis 104 (or a gasket member, such an additional piece of over drape surrounding the wound edges) by the attachment member 118 in order to form a fluid seal over the wound 102. As used herein, reference to forming a fluid seal with the patient's epidermis shall be deemed to also include forming a seal with a gasket proximate the wound 102.
  • The reduced-pressure interface 152 is applied, if not already installed, and the conduit 150 fluidly coupled at one end to the reduced-pressure interface 152. The other end of the conduit 150 is fluidly coupled to the reduced-pressure source 142. The reduced-pressure source 142 may be activated such that reduced pressure is delivered to the sealing member 110 and microstrain-inducing manifold 112. The reduced pressure provides reduced-pressure treatment to the tissue site 103, removes fluids, and may force the shaped projections 126 of the microstrain-inducing manifold 112 against the wound 102 such that they create a microstrain at the cellular level within the wound 102. As previously suggested, the microstrain may promote cellular proliferation, formation of granular tissue, and other beneficial effects. Alternatively, the microstrain-inducing manifold 112 may be placed proximate the tissue site 103 and then pressure may be applied by using a wrap over the microstrain-inducing manifold 112 or other source of pressure.
  • Referring now primarily to FIGS. 4A and 4B, an illustrative, non-limiting embodiment of a microstrain-inducing manifold 212 for use as part of a reduced-pressure wound treatment, such as the reduced-pressure wound treatment system 100 in FIG. 1, is shown. The microstrain-inducing manifold 212 includes interconnected nodes 224, which include shaped projections 226 extending from the interconnected nodes 224. In the illustrative embodiment, the shaped projections 226 are conical in shape; however, it will be appreciated that the shaped projections 226 may be any suitable shape capable of creating microstrain within a wound as previously discussed. Moreover, while each interconnected node 224 of the illustrative embodiment includes two projections 226 (one directed up and one directed down for the orientation shown in FIG. 4A), it will be appreciated that any number of projections 224 may extend from each interconnected node 224 or that some of the interconnected nodes 224 may have no projections 224. Also, in the illustrative embodiment, each projection 226 extends substantially normal from a corresponding interconnected node 224, but it will be appreciated that each projection 226 may extend from the corresponding interconnected node 224 at any angle.
  • The interconnected nodes 224 are spaced apart and interconnected by a network of connecting members 234 as clearly shown in FIG. 4B. The network of connecting members 234 includes a plurality of curved members 236. A plurality of flow channels 240 are formed between the interconnected nodes 224 and members 236. The members 236 have curved surfaces 290 that are curved in a cooperative manner with one another or with the radius of one or more corresponding interconnected nodes 224 such that when the microstrain-inducing manifold 212 is subjected to a reduced pressure, the microstrain-inducing manifold 212 collapses (partially or fully) in two directions (e.g., along the x-axis 286 and y-axis 288) but not at all or to a lesser extent in a third direction (e.g., the z-axis 284). As the microstrain-inducing manifold 212 collapses, each curved surface 290 of each member 236 abuts or approaches a curved surface 290 of an adjacent member 236 or at least one corresponding interconnected node 224. This may be particularly advantageous if the reduced-pressure wound treatment system is configured to assist in drawing the wound together during reduced pressure therapy.
  • Referring now primarily to FIGS. 5A and 5B, an illustrative, non-limiting embodiment of a manifold structure 412, which is a form of a microstrain-inducing manifold, is presented. The manifold structure 412 is for use with a reduced-pressure wound treatment system, such as the reduced-pressure wound treatment system 100 of FIG. 1, is shown. The manifold structure 412 includes one or more longitudinal members 456. The longitudinal members 456 may be coupled in a spaced relationship by lateral connecting members 460. The lateral connecting members 460 may be coupled to the longitudinal members 456. The longitudinal members 456 and lateral connecting members 460 are shown with circular cross-sections, but it should be appreciated that the longitudinal members 456 and lateral connecting members 460 may have any suitable cross-sectional shape. While reference is made to longitudinal and lateral members, the members 456, 460 need not be orthogonal but may have other relative angles.
  • Each longitudinal member 456 of the manifold structure 412 includes one or more shaped projections 426 for creating a microstrain within a wound. The longitudinal members 456 and shaped projections 426 are arranged such that the manifold structure 412 includes a plurality of flow channels 440 or pathways between adjacent longitudinal members 456 or between projections 426. The flow channels 440 facilitate distribution of fluids provided to and removed from the area of tissue around the manifold structure 412. It should be understood that any combination of longitudinal members 456 and lateral members 460 may be used. For example, the manifold structure 412 may be formed by a longitudinally connected group of longitudinal members 456 with projections 426. There are eight such longitudinal groups shown in FIG. 5A, and while shown with the lateral connecting members 460, the lateral connecting members 460 may be omitted in some embodiments. Moreover, while only lateral connecting members 460 are shown on the ends, it should be understood that any number of permutations are possible, and lateral members 460 may be distributed at various locations between the longitudinal members 456.
  • In the illustrative embodiment, each shaped projection 426 projects substantially normal from the corresponding longitudinal member 456. As used here, “normal” is a vector which perpendicular to that surface. For a non-flat surface, the normal vector may be taken at a point and is the same as a normal to the tangent plane at that point. It should be appreciated, however, that each shaped projection 426 may project at any angle relative to the corresponding longitudinal member 456. Each shaped projection 426 may include a columnar body 427, which has a first outer diameter (D1), and an enlarged member 429, which has a second outer diameter (D2). Each enlarged member 429 is positioned at the distal end of an associated columnar body 427. Each columnar body 429 may have any shape, e.g., the cross-section may be a circular, square, elliptical, irregular, etc., and may vary along its longitudinal dimension. The enlarged member 429 may be a spherical member as shown or may take any other shape, such as rounded cylindrical member, a cubical member, or an irregular shape. The second outer diameter (D2) of the enlarged member 429 is greater than the first outer diameter (D1) of the columnar body 427, i.e., D2>D1. In this regard, the shaped projections 426 may be considered to be tapered from a larger distal end to a smaller proximal end.
  • Each shaped projection 426 may have any suitable shape capable of creating a microstrain within the wound when the shaped projection 426 impinges upon the wound. Additionally, in the illustrative embodiment, the shaped projections 426 have substantially equal heights, but it will be appreciated that the shaped projections 426 may have varying heights along each longitudinal member 456 or among the plurality of longitudinal members 456. Also, it will be appreciated that certain portions of certain longitudinal members 456 may not have shaped projections 426 such that microstrain is not provided to certain areas within the wound. As with the microstrain-inducing manifolds previously discussed, the manifold structure 412 may be formed using any suitable process, including, but not limited to, micromolding, injection molding, casting, etc. The shaped projections 426 may be formed to be substantially integral with corresponding longitudinal members 456 or may be coupled to corresponding longitudinal members 456 by any suitable technique including, but not limited to, mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc.
  • In use, the manifold structure 412 is placed proximate the tissue site, e.g., wound, and a sealing member is deployed over the manifold structure 412 and tissue site. Reduced pressure may then be applied or alternatively a direct pressure may be applied. In some embodiments, e.g., embodiment with widely spaced lateral members 460, when the manifold structure 412 is subjected to a reduced pressure, the manifold structure 412 may behave anisotropically. In other words, when the manifold structure 412 is subjected to a reduced pressure, in addition to the shaped projections 426 being forced into the wound to create microstrain, the longitudinal members 456 may move laterally towards each other. Each longitudinal member 456 move closer to an adjacent longitudinal member 456 than the adjacent longitudinal members 456 were prior to the introduction of the reduced pressure. At the same time, the manifold structure 412 does not substantially contract in a direction substantially parallel to the longitudinal members 456.
  • If the lateral connecting members 460 are omitted, even further contraction may be possible. The manifold structure 412 may deform more in a direction substantially perpendicular to the longitudinal members 456 (as illustrated by arrows 458 in FIG. 5A) without a proportional deformation in the direction parallel with the longitudinal members 456. The deformation is typically within the same plane. This may be advantageous if the system employs other components, such as an anisotropic drape or another manifold, for drawing the wound together during reduced pressure therapy wherein the illustrative manifold structure 412 contracts in a manner complimentary therewith. If spaced lateral connecting members 460 are used in sufficient number, very little contraction may take place. In an alternative embodiment, the manifold structure 412 is configured such that some longitudinal members 456 are arranged substantially perpendicular to other longitudinal members 456 whereby the manifold structure 412 partially contracts, or contracts in a more limited manner, in two directions within the same plane when subjected to a reduced pressure.
  • Referring now primarily to FIGS. 6A and 6B, another illustrative, non-limiting embodiment of a microstrain-inducing manifold 512 for use with a reduced-pressure wound treatment system, such as a reduced-pressure wound treatment system 100 (FIG. 1), is shown. The microstrain-inducing manifold 512 includes a mat 558, or base, from which a plurality of shaped projections 526 extend. The mat 558 has a first side 513 and a second, patient-facing side 515. In the illustrative embodiment, the shaped projections 526 are tapered and in particular are substantially conical in shape, but it will be appreciated that the projections 526 may have any suitable shape capable of creating microstrain within the wound. Also, while the illustrative embodiment shows the projections 526 extending substantially normal, i.e., perpendicular, from the mat 558, it will be appreciated that the projections 526 may extend from the mat 558 at any suitable angle. Furthermore, in the illustrative embodiment, the projections 526 have substantially equal heights, but the mat 558 may include projections 526 of varying heights. Portions of the mat 558 may not have any projections such that microstrain is not provided to certain areas within the wound. Additionally, the stiffness of the shaped projections 526 and pitch of the shaped projections 526 may vary along the mat 558 such that the microstrain created by the projections 526 may be greater in certain areas of the wound versus other areas.
  • The shaped projections 526 may be formed as integral portions of the mat 558 or coupled to the mat 558 by any suitable techniques, including but not limited to mechanical fasteners, welding (e.g., ultrasonic or RF welding), bonding, adhesives, cements, etc. The mat 558 may also includes a plurality of apertures 560 (FIG. 6B) disposed between the projections 526 to improve the distribution of fluids provided to and removed from the area of tissue around the microstrain-inducing manifold 512. In an alternative embodiment, the shaped projections 526 may be formed from a modified honey on the mat 558. The honey may be modified so that it is solid or partially solid and retains its shape for at least a certain amount of time whilst engaging the wound. Advantageously, the honey may act as an antimicrobial agent and may be absorbed by the patient after a period of time. Other dissolvable substances may be used as well.
  • In operation, the microstrain-inducing manifold 512 is typically placed proximate the tissue site with the second, patient-facing side 515 facing the patient and covered with a sealing member. Reduced pressure is then delivered to the microstrain-inducing manifold 512. When subjected to a reduced pressure, the microstrain-inducing manifold 512 impinges on the wound whereby the shaped projections 526 create microstrain within the wound. Additionally, exudate and other fluids pass through the mat 558 via the apertures 560. Also, in some instances, it may be desirable to avoid increasing microstrain within the wound via the shaped projections 526. In such an instance, the microstrain-inducing manifold 512 may be inverted such that the first side 513 of the mat 558 is placed against the wound and the shaped projections 526 extend towards the sealing member (not shown). Thus, the microstrain-inducing manifold 512 may assist in perfusion and fluid removal (via the apertures 560) without also increasing microstrain within the wound via the shaped projections 526.
  • Referring now primarily to FIG. 7, an illustrative, non-limiting embodiment of a microstrain-inducing manifold member 624 for use with a reduced-pressure wound treatment system, such as the reduced-pressure wound treatment system 100 in FIG. 1, is shown. A microstrain-inducing manifold may be formed by a plurality of microstrain-inducing manifolds 624. Each microstrain-inducing manifold member 624 has one or more shaped projections 626 extending from a surface 631. Unlike the reduced-pressure wound treatment system 100 of FIGS. 1-3B, the microstrain-inducing manifold members 624 are not interconnected by a network of connecting members. Rather, a plurality of microstrain-inducing manifold members 624 may be poured into a wound whereby they work together to form the microstrain-inducing manifold in the wound (in situ) and whereby the shaped projections 626 of the microstrain-inducing manifold members 624 contact the wound to create microstrain therein. The plurality of microstrain-inducing manifold members 624 may fill the entire wound. Alternatively, the plurality of microstrain-inducing manifold members 624 may partially fill the wound, and, optionally, an alternative manifold may be placed atop the microstrain-inducing manifold members 624 to fill the wound.
  • In another alternative, the microstrain-inducing manifold members 624 may have a coating of material that allows the microstrain-inducing manifold members 624 to fuse or sinter in situ to one another and form a single, integral manifold. Non-limiting examples of coatings include the following: any water soluble, swellable, or softenable material, including polymers such as poly vinyl alcohol and its copolymer, polyvinyl pyrrolidone and its copolymers, polyethylene oxide and its copolymers, polypropylene oxide and its copolymers, hydroxyl, carboxyl, and sulphonyl containing polymers (e.g., hydroxyl ethyl acrylate, carboxyl methyl cellulose, acrylamido methyl propane sulphonic acid and its salts), alginates, gums (e.g. xanthan and guar), other hydrogels and hydrocolloids.
  • Although the present invention and its advantages have been disclosed in the context of certain illustrative, non-limiting embodiments, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope of the invention as defined by the appended claims. It will be appreciated that any feature that is described in a connection to any one embodiment may also be applicable to any other embodiment.

Claims (20)

We claim:
1. An apparatus for placement at a tissue site, comprising:
a plurality of nodes, each node having a substantially circular cross section;
a plurality of shaped projections, each shaped projection coupled to one of the plurality of nodes, each shaped projection comprising a conical shape; and
a plurality of connecting members, each connecting member coupled to at least one of the plurality of nodes at a first end of the connecting member, each connecting member coupled to at least one other node of the plurality of nodes at a second end of the connecting member, each connecting member comprising a substantially circular cross section.
2. The apparatus of claim 1, wherein the apparatus is formed from an elastomer.
3. The apparatus of claim 1, wherein the apparatus is formed from a bioabsorbable polymer.
4. The apparatus of claim 1, wherein the apparatus is formed from a biodegradable polymer.
5. The apparatus of claim 1, wherein the apparatus comprises a radio opaque material
6. The apparatus of claim 1, wherein the apparatus comprises a UV fluorescent material.
7. The apparatus of claim 1, wherein each of the plurality of nodes is substantially coplanar with an adjacent node.
8. The apparatus of claim 1, wherein the plurality of shaped projections comprises a first plurality of shaped projections having a first pitch and a second plurality of shaped projections having a second pitch, each of the plurality of nodes having at least one shaped projection from the first plurality of shaped projections and one shaped projection from the second plurality of shaped projections.
9. The apparatus of claim 8, wherein the first pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the first plurality of shaped projections.
10. The apparatus of claim 8, wherein the second pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the second plurality of shaped projections.
11. A system for treating a tissue site, comprising:
a manifold configured to be placed at the tissue site, the manifold comprising:
a plurality of nodes, each node having a substantially circular cross section, a plurality of shaped projections, each shaped projection coupled to one of the plurality of nodes, each shaped projection comprising a conical shape, and
a plurality of connecting members, each connecting member coupled to at least one of the plurality of nodes at a first end of the connecting member, each connecting member coupled to at least one other node of the plurality of nodes at a second end of the connecting member, each connecting member comprising a substantially circular cross section;
a flexible sheet configured to be disposed over the manifold, the flexible sheet configured to form a fluid seal over the tissue site; and
a reduced-pressure source configured to be fluidly coupled to the tissue site through the flexible sheet.
12. The system of claim 11, wherein the manifold is formed from an elastomer.
13. The system of claim 11, wherein the manifold is formed from a bioabsorbable polymer.
14. The system of claim 11, wherein the manifold is formed from a biodegradable polymer.
15. The system of claim 11, wherein the manifold comprises a radio opaque material
16. The system of claim 11, wherein the manifold comprises a UV fluorescent material.
17. The system of claim 11, wherein each of the plurality of nodes is substantially coplanar with an adjacent node.
18. The system of claim 11, wherein the plurality of shaped projections comprises a first plurality of shaped projections having a first pitch and a second plurality of shaped projections having a second pitch, each of the plurality of nodes having at least one shaped projection from the first plurality of shaped projections and one shaped projection from the second plurality of shaped projections.
19. The system of claim 18, wherein the first pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the first plurality of shaped projections.
20. The system of claim 18, wherein the second pitch is defined by an angle between a reference line formed to have a right angle with a longitudinal axis of the shaped projection and an outer surface of the shaped projection from the second plurality of shaped projections.
US16/733,055 2008-12-24 2020-01-02 Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds Abandoned US20200147280A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/733,055 US20200147280A1 (en) 2008-12-24 2020-01-02 Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14066208P 2008-12-24 2008-12-24
US12/639,253 US8529528B2 (en) 2008-12-24 2009-12-16 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US13/963,809 US9622915B2 (en) 2008-12-24 2013-08-09 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US15/448,793 US10561768B2 (en) 2008-12-24 2017-03-03 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US16/733,055 US20200147280A1 (en) 2008-12-24 2020-01-02 Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US15/448,793 Continuation US10561768B2 (en) 2008-12-24 2017-03-03 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds

Publications (1)

Publication Number Publication Date
US20200147280A1 true US20200147280A1 (en) 2020-05-14

Family

ID=42267164

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/639,253 Active 2031-09-23 US8529528B2 (en) 2008-12-24 2009-12-16 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US13/963,809 Active 2032-04-02 US9622915B2 (en) 2008-12-24 2013-08-09 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US15/448,793 Active 2031-03-13 US10561768B2 (en) 2008-12-24 2017-03-03 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US16/733,055 Abandoned US20200147280A1 (en) 2008-12-24 2020-01-02 Reduced-Pressure Wound Treatment Systems And Methods Employing Microstrain-Inducing Manifolds

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US12/639,253 Active 2031-09-23 US8529528B2 (en) 2008-12-24 2009-12-16 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US13/963,809 Active 2032-04-02 US9622915B2 (en) 2008-12-24 2013-08-09 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US15/448,793 Active 2031-03-13 US10561768B2 (en) 2008-12-24 2017-03-03 Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds

Country Status (13)

Country Link
US (4) US8529528B2 (en)
EP (3) EP3669850A1 (en)
JP (1) JP5613173B2 (en)
KR (1) KR20110116140A (en)
CN (1) CN102264333B (en)
AU (2) AU2009330298B2 (en)
BR (1) BRPI0918310A2 (en)
CA (1) CA2745695C (en)
MX (1) MX2011006806A (en)
RU (1) RU2011122962A (en)
SG (1) SG172011A1 (en)
TW (1) TW201029697A (en)
WO (1) WO2010075179A2 (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
GB0804654D0 (en) * 2008-03-13 2008-04-16 Smith & Nephew Vacuum closure device
CN102256638B (en) * 2008-12-24 2014-04-23 凯希特许有限公司 Membranes, systems, and methods for applying reduced pressure to a subcutaneous tissue site
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
US8882730B2 (en) 2010-03-12 2014-11-11 Kci Licensing, Inc. Radio opaque, reduced-pressure manifolds, systems, and methods
US9358158B2 (en) * 2010-03-16 2016-06-07 Kci Licensing, Inc. Patterned neo-epithelialization dressings, systems, and methods
US9421132B2 (en) 2011-02-04 2016-08-23 University Of Massachusetts Negative pressure wound closure device
EP2670312B1 (en) 2011-02-04 2020-11-18 University of Massachusetts Negative pressure wound closure device
CN103619366B (en) 2011-04-15 2018-02-16 马萨诸塞州大学 Surgical cavity drainage and closed-system
AU2012266095B2 (en) * 2011-06-07 2016-05-05 Smith & Nephew Plc Wound contacting members and methods
JP6224581B2 (en) * 2011-06-24 2017-11-01 ケーシーアイ ライセンシング インコーポレイテッド Reduced pressure dressing with tissue fixation elements
EP2782606B1 (en) 2011-11-21 2021-01-20 3M Innovative Properties Company Systems, devices, and methods for identifying portions of a wound filler left at a tissue site
WO2013096091A1 (en) * 2011-12-21 2013-06-27 Kci Licensing, Inc. A wound filler having dynamic motion
EP2814556B1 (en) * 2012-02-13 2016-12-07 Integrated Healing Technologies Wound dressing apparatus
CA3122007A1 (en) 2012-03-12 2013-09-19 Smith & Nephew Plc Reduced pressure apparatus and methods
CA2874396A1 (en) 2012-05-22 2014-01-23 Smith & Nephew Plc Wound closure device
AU2013264938B2 (en) 2012-05-22 2017-11-23 Smith & Nephew Plc Apparatuses and methods for wound therapy
AU2013264937B2 (en) 2012-05-24 2018-04-19 Smith & Nephew Inc. Devices and methods for treating and closing wounds with negative pressure
RU2015104581A (en) 2012-07-16 2016-09-10 Смит Энд Нефью, Инк. DEVICE FOR CLOSING THE Wound USING NEGATIVE PRESSURE
WO2014024048A1 (en) * 2012-08-08 2014-02-13 Smith & Nephew Plc Bespoke wound treatment apparatuses and methods for use in negative pressure wound therapy
USD738487S1 (en) * 2013-01-28 2015-09-08 Molnlycke Health Care Ab Suction device for negative pressure therapy
RU2015142873A (en) 2013-03-13 2017-04-19 Смит Энд Нефью Инк. DEVICE AND SYSTEMS FOR CLOSING A Wound USING NEGATIVE PRESSURE, AND METHODS FOR APPLICATION IN TREATING A WAN USING NEGATIVE PRESSURE
WO2014140578A1 (en) 2013-03-14 2014-09-18 Smith & Nephew Plc Compressible wound fillers and systems and methods of use in treating wounds with negative pressure
JP6560201B2 (en) * 2013-07-10 2019-08-14 ケーシーアイ ライセンシング インコーポレイテッド Manually regulated negative pressure pump with adapter for external pressure source
CN105530898B (en) 2013-07-16 2020-02-28 史密夫及内修公开有限公司 Apparatus for wound therapy
US10342891B2 (en) * 2013-09-19 2019-07-09 Medline Industries, Inc. Wound dressing containing saccharide and collagen
AU2014340232B2 (en) 2013-10-21 2019-07-11 Smith & Nephew Inc. Negative pressure wound closure device
US10201642B2 (en) 2014-01-21 2019-02-12 Smith & Nephew Plc Collapsible dressing for negative pressure wound treatment
US10179073B2 (en) 2014-01-21 2019-01-15 Smith & Nephew Plc Wound treatment apparatuses
JP2017512620A (en) * 2014-03-28 2017-05-25 スリーエム イノベイティブ プロパティズ カンパニー Articles and methods for negative pressure wound closure therapy
EP3797744A1 (en) 2014-05-09 2021-03-31 3M Innovative Properties Company Dressing with contracting layer for linear tissue sites
AU2015255726B2 (en) 2014-05-09 2020-03-05 Solventum Intellectual Properties Company Disruptive dressing for use with negative pressure and fluid instillation
US10898217B2 (en) 2014-05-09 2021-01-26 Kci Licensing, Inc. Dressing providing apertures with multiple orifice sizes for negative-pressure therapy
WO2016174048A1 (en) 2015-04-27 2016-11-03 Smith & Nephew Plc Reduced pressure apparatuses
AU2016254119A1 (en) 2015-04-29 2017-10-05 Smith & Nephew Inc. Negative pressure wound closure device
US10064273B2 (en) 2015-10-20 2018-08-28 MR Label Company Antimicrobial copper sheet overlays and related methods for making and using
US10575991B2 (en) 2015-12-15 2020-03-03 University Of Massachusetts Negative pressure wound closure devices and methods
US10814049B2 (en) 2015-12-15 2020-10-27 University Of Massachusetts Negative pressure wound closure devices and methods
US11723809B2 (en) 2016-03-07 2023-08-15 Smith & Nephew Plc Wound treatment apparatuses and methods with negative pressure source integrated into wound dressing
CN109121396B (en) 2016-04-26 2022-04-05 史密夫及内修公开有限公司 Wound dressing and method for use with an integrated negative pressure source having a fluid intrusion inhibiting feature
EP3452129B1 (en) 2016-05-03 2022-03-23 Smith & Nephew plc Negative pressure wound therapy device activation and control
US11305047B2 (en) 2016-05-03 2022-04-19 Smith & Nephew Plc Systems and methods for driving negative pressure sources in negative pressure therapy systems
WO2017191149A1 (en) 2016-05-03 2017-11-09 Smith & Nephew Plc Optimizing power transfer to negative pressure sources in negative pressure therapy systems
WO2018037075A1 (en) 2016-08-25 2018-03-01 Smith & Nephew Plc Absorbent negative pressure wound therapy dressing
WO2018041805A1 (en) 2016-08-30 2018-03-08 Smith & Nephew Plc Systems for applying reduced pressure therapy
WO2018060144A1 (en) 2016-09-27 2018-04-05 Smith & Nephew Plc Wound closure devices with dissolvable portions
WO2018060417A1 (en) 2016-09-30 2018-04-05 Smith & Nephew Plc Negative pressure wound treatment apparatuses and methods with integrated electronics
JP2019532774A (en) 2016-11-02 2019-11-14 スミス アンド ネフュー インコーポレイテッド Wound closure device
AU2017375560B2 (en) 2016-12-12 2023-07-06 Smith & Nephew Plc Pressure wound therapy status indication via external device
CA3055664A1 (en) 2017-03-08 2018-09-13 Smith & Nephew Plc Negative pressure wound therapy device control in presence of fault condition
WO2018191274A1 (en) * 2017-04-11 2018-10-18 University Of Florida Research Foundation Systems and methods for in-situ, bottom-up tissue generation
WO2018206420A1 (en) 2017-05-09 2018-11-15 Smith & Nephew Plc Redundant controls for negative pressure wound therapy systems
AU201716716S (en) 2017-05-11 2017-11-21 MAƒA¶LNLYCKE HEALTH CARE AB Wound dressings
WO2018229009A1 (en) 2017-06-13 2018-12-20 Smith & Nephew Plc Wound closure device and method of use
US11324876B2 (en) 2017-06-13 2022-05-10 Smith & Nephew Plc Collapsible structure and method of use
EP3638174A1 (en) 2017-06-14 2020-04-22 Smith & Nephew plc Collapsible sheet for wound closure and method of use
US11123476B2 (en) 2017-06-14 2021-09-21 Smith & Nephew, Inc. Fluid removal management and control of wound closure in wound therapy
EP3638170B1 (en) 2017-06-14 2024-03-13 Smith & Nephew PLC Collapsible structure for wound closure and method of use
EP3638173A1 (en) 2017-06-14 2020-04-22 Smith & Nephew, Inc Control of wound closure and fluid removal management in wound therapy
US10751212B2 (en) * 2017-06-26 2020-08-25 Maryam Raza Multilayer dressing device and method for preventing and treating pressure ulcers and chronic wounds
WO2019020544A1 (en) 2017-07-27 2019-01-31 Smith & Nephew Plc Customizable wound closure device and method of use
WO2019030136A1 (en) 2017-08-07 2019-02-14 Smith & Nephew Plc Wound closure device with protective layer and method of use
US11375923B2 (en) 2017-08-29 2022-07-05 Smith & Nephew Plc Systems and methods for monitoring wound closure
WO2019053101A1 (en) 2017-09-13 2019-03-21 Smith & Nephew Plc Negative pressure wound treatment apparatuses and methods with integrated electronics
GB201718070D0 (en) 2017-11-01 2017-12-13 Smith & Nephew Negative pressure wound treatment apparatuses and methods with integrated electronics
GB201718072D0 (en) 2017-11-01 2017-12-13 Smith & Nephew Negative pressure wound treatment apparatuses and methods with integrated electronics
EP3703632B1 (en) 2017-11-01 2024-04-03 Smith & Nephew plc Negative pressure wound treatment apparatuses and methods with integrated electronics
GB201718054D0 (en) 2017-11-01 2017-12-13 Smith & Nephew Sterilization of integrated negative pressure wound treatment apparatuses and sterilization methods
US11511032B2 (en) 2018-03-12 2022-11-29 Kci Licensing, Inc. Dressing using differential surface features for use in compartment spaces
CN112040915B (en) * 2018-03-26 2022-04-01 帝皇工业有限公司 Multi-lumen bridge for negative pressure wound therapy system
WO2020005535A1 (en) * 2018-06-28 2020-01-02 Kci Licensing, Inc. A highly conformable wound dressing
US20200038283A1 (en) * 2018-08-01 2020-02-06 Kci Licensing, Inc. Soft-Tissue Treatment With Negative Pressure
USD898925S1 (en) 2018-09-13 2020-10-13 Smith & Nephew Plc Medical dressing
US20210338490A1 (en) * 2018-10-17 2021-11-04 Kci Licensing, Inc. Systems, Apparatuses, And Methods For Negative-Pressure Treatment With Reduced Tissue In-Growth
US20200146896A1 (en) * 2018-11-08 2020-05-14 Kci Licensing, Inc. Dressing with protruding layer allowing for cleansing of wound bed macro deformations
WO2020124038A1 (en) 2018-12-13 2020-06-18 University Of Massachusetts Negative pressure wound closure devices and methods
JP2022520048A (en) * 2019-02-07 2022-03-28 ケーシーアイ ライセンシング インコーポレイテッド Contoured foam dressing shaped to provide negative pressure for the shoulder incision
GB201903774D0 (en) 2019-03-20 2019-05-01 Smith & Nephew Negative pressure wound treatment apparatuses and methods with integrated electronics
GB201907716D0 (en) 2019-05-31 2019-07-17 Smith & Nephew Systems and methods for extending operational time of negative pressure wound treatment apparatuses
AU2020294577B2 (en) * 2019-06-20 2023-09-28 Kuo Huang YANG Fluid-carrying application
US20230301835A1 (en) * 2020-07-30 2023-09-28 3M Innovative Properties Company Low-growth tissue interface
USD1043997S1 (en) * 2020-09-18 2024-09-24 Jake Timothy Compression wound dressing

Family Cites Families (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1355846A (en) 1920-02-06 1920-10-19 David A Rannells Medical appliance
US2547758A (en) * 1949-01-05 1951-04-03 Wilmer B Keeling Instrument for treating the male urethra
US2632443A (en) * 1949-04-18 1953-03-24 Eleanor P Lesher Surgical dressing
GB692578A (en) 1949-09-13 1953-06-10 Minnesota Mining & Mfg Improvements in or relating to drape sheets for surgical use
US2682873A (en) * 1952-07-30 1954-07-06 Johnson & Johnson General purpose protective dressing
NL189176B (en) 1956-07-13 1900-01-01 Hisamitsu Pharmaceutical Co PLASTER BASED ON A SYNTHETIC RUBBER.
US2969057A (en) * 1957-11-04 1961-01-24 Brady Co W H Nematodic swab
US2930377A (en) * 1958-06-02 1960-03-29 Baxter Don Inc Surgical tube
US3066672A (en) 1960-09-27 1962-12-04 Jr William H Crosby Method and apparatus for serial sampling of intestinal juice
US3407817A (en) 1965-07-26 1968-10-29 Air Reduction Inc Catheter with cuff inflater and indicator
US3367332A (en) * 1965-08-27 1968-02-06 Gen Electric Product and process for establishing a sterile area of skin
US3520300A (en) * 1967-03-15 1970-07-14 Amp Inc Surgical sponge and suction device
US3568675A (en) * 1968-08-30 1971-03-09 Clyde B Harvey Fistula and penetrating wound dressing
US3630206A (en) 1970-01-02 1971-12-28 Bruce Gingold Bladder catheter
US3599641A (en) * 1970-03-13 1971-08-17 David S Sheridan Combination connector and channel closure system for catheters
US3682180A (en) * 1970-06-08 1972-08-08 Coilform Co Inc Drain clip for surgical drain
BE789293Q (en) * 1970-12-07 1973-01-15 Parke Davis & Co MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS
US3826254A (en) * 1973-02-26 1974-07-30 Verco Ind Needle or catheter retaining appliance
DE2527706A1 (en) * 1975-06-21 1976-12-30 Hanfried Dr Med Weigand DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET
DE2640413C3 (en) 1976-09-08 1980-03-27 Richard Wolf Gmbh, 7134 Knittlingen Catheter monitor
NL7710909A (en) * 1976-10-08 1978-04-11 Smith & Nephew COMPOSITE STRAPS.
GB1562244A (en) 1976-11-11 1980-03-05 Lock P M Wound dressing materials
US4080970A (en) * 1976-11-17 1978-03-28 Miller Thomas J Post-operative combination dressing and internal drain tube with external shield and tube connector
US4139004A (en) * 1977-02-17 1979-02-13 Gonzalez Jr Harry Bandage apparatus for treating burns
US4184510A (en) * 1977-03-15 1980-01-22 Fibra-Sonics, Inc. Valued device for controlling vacuum in surgery
US4165748A (en) * 1977-11-07 1979-08-28 Johnson Melissa C Catheter tube holder
US4256109A (en) * 1978-07-10 1981-03-17 Nichols Robert L Shut off valve for medical suction apparatus
SE414994B (en) * 1978-11-28 1980-09-01 Landstingens Inkopscentral VENKATETERFORBAND
GB2047543B (en) * 1978-12-06 1983-04-20 Svedman Paul Device for treating tissues for example skin
US4266545A (en) 1979-04-06 1981-05-12 Moss James P Portable suction device for collecting fluids from a closed wound
US4284079A (en) * 1979-06-28 1981-08-18 Adair Edwin Lloyd Method for applying a male incontinence device
US4261363A (en) * 1979-11-09 1981-04-14 C. R. Bard, Inc. Retention clips for body fluid drains
US4569348A (en) * 1980-02-22 1986-02-11 Velcro Usa Inc. Catheter tube holder strap
ATE14835T1 (en) 1980-03-11 1985-08-15 Schmid Eduard SKIN GRAFT PRESSURE BANDAGE.
US4297995A (en) 1980-06-03 1981-11-03 Key Pharmaceuticals, Inc. Bandage containing attachment post
US4333468A (en) * 1980-08-18 1982-06-08 Geist Robert W Mesentery tube holder apparatus
US4398910A (en) * 1981-02-26 1983-08-16 Blake L W Wound drain catheter
US4465485A (en) * 1981-03-06 1984-08-14 Becton, Dickinson And Company Suction canister with unitary shut-off valve and filter features
US4392853A (en) * 1981-03-16 1983-07-12 Rudolph Muto Sterile assembly for protecting and fastening an indwelling device
SE8103617L (en) * 1981-06-09 1982-12-10 Meteve Ab CATS FOR POST-OPERATIVE DRAINAGE
US4373519A (en) * 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4392858A (en) * 1981-07-16 1983-07-12 Sherwood Medical Company Wound drainage device
US4419097A (en) 1981-07-31 1983-12-06 Rexar Industries, Inc. Attachment for catheter tube
AU550575B2 (en) 1981-08-07 1986-03-27 Richard Christian Wright Wound drainage device
SE429197B (en) * 1981-10-14 1983-08-22 Frese Nielsen SAR TREATMENT DEVICE
DE3146266A1 (en) * 1981-11-21 1983-06-01 B. Braun Melsungen Ag, 3508 Melsungen COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE
US4551139A (en) 1982-02-08 1985-11-05 Marion Laboratories, Inc. Method and apparatus for burn wound treatment
US4475909A (en) 1982-05-06 1984-10-09 Eisenberg Melvin I Male urinary device and method for applying the device
EP0100148B1 (en) 1982-07-06 1986-01-08 Dow Corning Limited Medical-surgical dressing and a process for the production thereof
NZ206837A (en) 1983-01-27 1986-08-08 Johnson & Johnson Prod Inc Thin film adhesive dressing:backing material in three sections
US4548202A (en) 1983-06-20 1985-10-22 Ethicon, Inc. Mesh tissue fasteners
US4540412A (en) * 1983-07-14 1985-09-10 The Kendall Company Device for moist heat therapy
US4543100A (en) * 1983-11-01 1985-09-24 Brodsky Stuart A Catheter and drain tube retainer
US4525374A (en) * 1984-02-27 1985-06-25 Manresa, Inc. Treating hydrophobic filters to render them hydrophilic
GB2157958A (en) 1984-05-03 1985-11-06 Ernest Edward Austen Bedding Ball game net support
US4897081A (en) * 1984-05-25 1990-01-30 Thermedics Inc. Percutaneous access device
US5215522A (en) * 1984-07-23 1993-06-01 Ballard Medical Products Single use medical aspirating device and method
GB8419745D0 (en) * 1984-08-02 1984-09-05 Smith & Nephew Ass Wound dressing
US4872450A (en) 1984-08-17 1989-10-10 Austad Eric D Wound dressing and method of forming same
US4826494A (en) * 1984-11-09 1989-05-02 Stryker Corporation Vacuum wound drainage system
US4655754A (en) * 1984-11-09 1987-04-07 Stryker Corporation Vacuum wound drainage system and lipids baffle therefor
US4605399A (en) * 1984-12-04 1986-08-12 Complex, Inc. Transdermal infusion device
US5037397A (en) * 1985-05-03 1991-08-06 Medical Distributors, Inc. Universal clamp
US4640688A (en) * 1985-08-23 1987-02-03 Mentor Corporation Urine collection catheter
US4710165A (en) 1985-09-16 1987-12-01 Mcneil Charles B Wearable, variable rate suction/collection device
US4758220A (en) * 1985-09-26 1988-07-19 Alcon Laboratories, Inc. Surgical cassette proximity sensing and latching apparatus
US4733659A (en) * 1986-01-17 1988-03-29 Seton Company Foam bandage
WO1987004626A1 (en) 1986-01-31 1987-08-13 Osmond, Roger, L., W. Suction system for wound and gastro-intestinal drainage
US4838883A (en) * 1986-03-07 1989-06-13 Nissho Corporation Urine-collecting device
JPS62281965A (en) * 1986-05-29 1987-12-07 テルモ株式会社 Catheter and catheter fixing member
GB8621884D0 (en) * 1986-09-11 1986-10-15 Bard Ltd Catheter applicator
GB2195255B (en) 1986-09-30 1991-05-01 Vacutec Uk Limited Apparatus for vacuum treatment of an epidermal surface
US4743232A (en) * 1986-10-06 1988-05-10 The Clinipad Corporation Package assembly for plastic film bandage
DE3634569A1 (en) 1986-10-10 1988-04-21 Sachse Hans E CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS
JPS63135179A (en) * 1986-11-26 1988-06-07 立花 俊郎 Subcataneous drug administration set
GB8628564D0 (en) 1986-11-28 1987-01-07 Smiths Industries Plc Anti-foaming agent suction apparatus
GB8706116D0 (en) * 1987-03-14 1987-04-15 Smith & Nephew Ass Adhesive dressings
US4787888A (en) 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US4863449A (en) * 1987-07-06 1989-09-05 Hollister Incorporated Adhesive-lined elastic condom cathether
US5176663A (en) * 1987-12-02 1993-01-05 Pal Svedman Dressing having pad with compressibility limiting elements
US4906240A (en) * 1988-02-01 1990-03-06 Matrix Medica, Inc. Adhesive-faced porous absorbent sheet and method of making same
US4985019A (en) * 1988-03-11 1991-01-15 Michelson Gary K X-ray marker
GB8812803D0 (en) 1988-05-28 1988-06-29 Smiths Industries Plc Medico-surgical containers
US4919654A (en) * 1988-08-03 1990-04-24 Kalt Medical Corporation IV clamp with membrane
US5000741A (en) 1988-08-22 1991-03-19 Kalt Medical Corporation Transparent tracheostomy tube dressing
DE69017479T2 (en) * 1989-01-16 1995-07-13 Roussel Uclaf Azabicyclohepten derivatives and their salts, processes for their preparation, their use as medicaments and preparations containing them.
GB8906100D0 (en) 1989-03-16 1989-04-26 Smith & Nephew Laminates
US5527293A (en) * 1989-04-03 1996-06-18 Kinetic Concepts, Inc. Fastening system and method
US5261893A (en) 1989-04-03 1993-11-16 Zamierowski David S Fastening system and method
US4969880A (en) 1989-04-03 1990-11-13 Zamierowski David S Wound dressing and treatment method
US5100396A (en) * 1989-04-03 1992-03-31 Zamierowski David S Fluidic connection system and method
US5358494A (en) 1989-07-11 1994-10-25 Svedman Paul Irrigation dressing
JP2719671B2 (en) * 1989-07-11 1998-02-25 日本ゼオン株式会社 Wound dressing
US5232453A (en) * 1989-07-14 1993-08-03 E. R. Squibb & Sons, Inc. Catheter holder
GB2235877A (en) 1989-09-18 1991-03-20 Antonio Talluri Closed wound suction apparatus
US5134994A (en) * 1990-02-12 1992-08-04 Say Sam L Field aspirator in a soft pack with externally mounted container
US5092858A (en) * 1990-03-20 1992-03-03 Becton, Dickinson And Company Liquid gelling agent distributor device
JP2941918B2 (en) 1990-09-19 1999-08-30 テルモ株式会社 Weighing device
US5149331A (en) * 1991-05-03 1992-09-22 Ariel Ferdman Method and device for wound closure
US5278100A (en) * 1991-11-08 1994-01-11 Micron Technology, Inc. Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers
US5645081A (en) * 1991-11-14 1997-07-08 Wake Forest University Method of treating tissue damage and apparatus for same
US5636643A (en) * 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US5279550A (en) * 1991-12-19 1994-01-18 Gish Biomedical, Inc. Orthopedic autotransfusion system
US5167613A (en) 1992-03-23 1992-12-01 The Kendall Company Composite vented wound dressing
FR2690617B1 (en) * 1992-04-29 1994-06-24 Cbh Textile TRANSPARENT ADHESIVE DRESSING.
GB9225581D0 (en) * 1992-12-08 1993-01-27 Courtaulds Plc Wound dressings
DE4306478A1 (en) 1993-03-02 1994-09-08 Wolfgang Dr Wagner Drainage device, in particular pleural drainage device, and drainage method
US6241747B1 (en) * 1993-05-03 2001-06-05 Quill Medical, Inc. Barbed Bodily tissue connector
US5342376A (en) * 1993-05-03 1994-08-30 Dermagraphics, Inc. Inserting device for a barbed tissue connector
US5344415A (en) * 1993-06-15 1994-09-06 Deroyal Industries, Inc. Sterile system for dressing vascular access site
US5437651A (en) * 1993-09-01 1995-08-01 Research Medical, Inc. Medical suction apparatus
US5549584A (en) * 1994-02-14 1996-08-27 The Kendall Company Apparatus for removing fluid from a wound
GB9411429D0 (en) 1994-06-08 1994-07-27 Seton Healthcare Group Plc Wound dressings
US5556375A (en) * 1994-06-16 1996-09-17 Hercules Incorporated Wound dressing having a fenestrated base layer
US5607388A (en) * 1994-06-16 1997-03-04 Hercules Incorporated Multi-purpose wound dressing
US5664270A (en) 1994-07-19 1997-09-09 Kinetic Concepts, Inc. Patient interface system
PT853950E (en) 1994-08-22 2003-03-31 Kinetic Concepts Inc WASTE DRAIN BOX
DE29504378U1 (en) 1995-03-15 1995-09-14 MTG Medizinisch, technische Gerätebau GmbH, 66299 Friedrichsthal Electronically controlled low-vacuum pump for chest and wound drainage
GB9523253D0 (en) 1995-11-14 1996-01-17 Mediscus Prod Ltd Portable wound treatment apparatus
US6099513A (en) * 1996-08-27 2000-08-08 Allegiance Corporation Wound drain with alternating perimetrically arranged lumens and ducts
NL1006457C2 (en) 1997-07-03 1999-01-05 Polymedics N V Drainage system to be used with an open wound, element used for applying a drainage pipe or hose and method for applying the drainage system.
US6135116A (en) 1997-07-28 2000-10-24 Kci Licensing, Inc. Therapeutic method for treating ulcers
US7273054B2 (en) * 1997-09-12 2007-09-25 Kci Licensing, Inc. Surgical drape and head for wound treatment
AU755496B2 (en) 1997-09-12 2002-12-12 Kci Licensing, Inc. Surgical drape and suction head for wound treatment
GB9719520D0 (en) 1997-09-12 1997-11-19 Kci Medical Ltd Surgical drape and suction heads for wound treatment
US6071267A (en) * 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
US6488643B1 (en) 1998-10-08 2002-12-03 Kci Licensing, Inc. Wound healing foot wrap
US6287316B1 (en) * 1999-03-26 2001-09-11 Ethicon, Inc. Knitted surgical mesh
US7799004B2 (en) 2001-03-05 2010-09-21 Kci Licensing, Inc. Negative pressure wound treatment apparatus and infection identification system and method
US6856821B2 (en) * 2000-05-26 2005-02-15 Kci Licensing, Inc. System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure
US6991643B2 (en) * 2000-12-20 2006-01-31 Usgi Medical Inc. Multi-barbed device for retaining tissue in apposition and methods of use
US6478789B1 (en) 1999-11-15 2002-11-12 Allegiance Corporation Wound drain with portals to enable uniform suction
AU4176101A (en) 2000-02-24 2001-09-03 Venetec Int Inc Universal catheter anchoring system
US6685681B2 (en) * 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US7700819B2 (en) * 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US6540705B2 (en) * 2001-02-22 2003-04-01 Core Products International, Inc. Ankle brace providing upper and lower ankle adjustment
US7004915B2 (en) * 2001-08-24 2006-02-28 Kci Licensing, Inc. Negative pressure assisted tissue treatment system
WO2004018020A1 (en) * 2002-08-21 2004-03-04 Hill-Rom Services, Inc. Wound packing for preventing wound closure
US7846141B2 (en) * 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
US6979324B2 (en) * 2002-09-13 2005-12-27 Neogen Technologies, Inc. Closed wound drainage system
US7154017B2 (en) * 2002-12-31 2006-12-26 Ossur Hf Method for producing a wound dressing
GB0409443D0 (en) * 2004-04-28 2004-06-02 Smith & Nephew Apparatus
DE102004001594B4 (en) * 2004-01-09 2006-09-21 Bio-Gate Ag Wound dressing and process for its preparation
US7754937B2 (en) * 2004-03-18 2010-07-13 Boehringer Technologies, L.P. Wound packing material for use with suction
US7951124B2 (en) * 2004-04-13 2011-05-31 Boehringer Technologies, Lp Growth stimulating wound dressing with improved contact surfaces
US7884258B2 (en) * 2004-04-13 2011-02-08 Boehringer Technologies, L.P. Wound contact device
GB2415382A (en) * 2004-06-21 2005-12-28 Johnson & Johnson Medical Ltd Wound dressings for vacuum therapy
US7438705B2 (en) * 2005-07-14 2008-10-21 Boehringer Technologies, L.P. System for treating a wound with suction and method detecting loss of suction
US7879615B2 (en) * 2005-10-20 2011-02-01 Coramed Technologies, Llc Hemostasis analyzer and method
AU2007206054B2 (en) * 2006-01-23 2011-06-09 3M Innovative Properties Company System and method for treating a wound using ultrasonic debridement
AU2007212480B2 (en) 2006-02-06 2010-04-29 Solventum Intellectual Properties Company Systems and methods for improved connection to wound dressings in conjunction with reduced pressure wound treatment systems
WO2007092405A2 (en) * 2006-02-07 2007-08-16 Tyco Healthcare Group Lp Surgical wound dressing
NZ576472A (en) * 2006-09-26 2011-12-22 Boehringer Technologies Lp Pump system for negative pressure wound therapy
EP2079418B1 (en) * 2006-11-09 2014-07-16 KCI Licensing, Inc. Porous bioresorbable dressing conformable to a wound and methods of making same
WO2008104609A1 (en) * 2007-03-01 2008-09-04 Coloplast A/S Pressure-distributing elements for use with negative pressure therapy
CN101801311A (en) 2007-05-01 2010-08-11 布赖汉姆妇女医院有限公司 Wound healing device
JP5243526B2 (en) * 2007-05-10 2013-07-24 ケーシーアイ ライセンシング インコーポレイテッド Depressurized wound dressing comprising a wound contact surface having columnar protrusions
GB0724039D0 (en) * 2007-12-08 2008-01-16 Smith & Nephew Wound fillers
GB0724040D0 (en) * 2007-12-08 2008-01-16 Smith & Nephew Wound packing members
AU2009251242B2 (en) * 2008-05-30 2013-08-15 Solventum Intellectual Properties Company Super-absorbent, reduced-pressure wound dressing and systems

Also Published As

Publication number Publication date
AU2015285968B2 (en) 2017-06-01
EP2367518A2 (en) 2011-09-28
CN102264333B (en) 2014-08-27
BRPI0918310A2 (en) 2019-09-24
SG172011A1 (en) 2011-07-28
WO2010075179A2 (en) 2010-07-01
AU2015285968A1 (en) 2016-02-04
AU2009330298A1 (en) 2010-07-01
CA2745695C (en) 2017-09-19
MX2011006806A (en) 2011-07-12
US20100160874A1 (en) 2010-06-24
CN102264333A (en) 2011-11-30
AU2009330298B2 (en) 2015-10-08
EP2367518B1 (en) 2017-10-25
KR20110116140A (en) 2011-10-25
JP5613173B2 (en) 2014-10-22
US9622915B2 (en) 2017-04-18
RU2011122962A (en) 2013-01-27
US20130324951A1 (en) 2013-12-05
EP2367518A4 (en) 2016-03-09
WO2010075179A3 (en) 2010-10-07
EP3292854A1 (en) 2018-03-14
EP3292854B1 (en) 2020-02-12
US10561768B2 (en) 2020-02-18
US20170224889A1 (en) 2017-08-10
JP2012513825A (en) 2012-06-21
EP3669850A1 (en) 2020-06-24
CA2745695A1 (en) 2010-07-01
TW201029697A (en) 2010-08-16
US8529528B2 (en) 2013-09-10

Similar Documents

Publication Publication Date Title
US10987454B2 (en) Reduced-pressure wound treatment systems and methods employing manifold structures
US10561768B2 (en) Reduced-pressure wound treatment systems and methods employing microstrain-inducing manifolds
US9421309B2 (en) Reduced-pressure treatment systems and methods employing hydrogel reservoir members

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

AS Assignment

Owner name: KCI LICENSING, INC., TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ROBINSON, TIMOTHY MARK;LOCKE, CHRISTOPHER BRIAN;TOUT, AIDAN MARCUS;SIGNING DATES FROM 20111021 TO 20111024;REEL/FRAME:052395/0134

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION